Medicare Part D coverage gap

Last updated

The Medicare Part D coverage gap (informally known as the Medicare donut hole) was a period of consumer payments for prescription medication costs that lay between the initial coverage limit and the catastrophic coverage threshold when the consumer was a member of a Medicare Part D prescription-drug program administered by the United States federal government. The gap was reached after a shared insurer payment - consumer payment for all covered prescription drugs reached a government-set amount, and was left only after the consumer had paid full, unshared costs of an additional amount for the same prescriptions. Upon entering the gap, the prescription payments to date were re-set to $0 and continued until the maximum amount of the gap was reached or the then current annual period lapses. In calculating whether the maximum amount of gap had been reached, the "True-out-of-pocket" costs (TrOOP) were added together.

Contents

A health insurance company provided this explanation about TrOOP:

"TrOOP includes the amount of your Initial Deductible (if any) and your co-payments or co-insurance during the Initial Coverage stage. While the Donut Hole includes what you pay when you fill a prescription and of the 75% Donut Hole discount on brand-name drugs, it includes the 70% Donut Hole Discount paid by the drug manufacturer. The additional 5% Donut Hole discount on brand-name drugs and the 75% Donut Hole discount on generics do not count toward TrOOP as they are paid by your Medicare Part D plan." [1]

TrOOP also included payments made for a consumer's drugs by any of the following programs or organizations: "Extra Help" from Medicare; Indian Health Service; AIDS drug assistance programs; most charities; and most State Pharmaceutical Assistance Programs (SPAPs).

Provisions of the Patient Protection and Affordable Care Act of 2010 gradually phased out the coverage gap, eliminating it in 2020. [2] : 1 

Details

In 2006, the first year of operation for Medicare Part D, the doughnut hole in the defined standard benefit covered a range in true out-of-pocket expenses (TrOOP) costs from $750 to $3,600. (The first $750 of TrOOP comes from a $250 deductible phase, and $500 in the initial coverage limit, in which the Centers for Medicare and Medicaid Services (CMS) covers 75 percent of the next $2,000.) In the first year of operation, there was a substantial reduction in out-of-pocket costs and a moderate increase in medication utilization among Medicare beneficiaries, although there was no evidence of improvement in emergency department use, hospitalizations, or preference-based health utility for those eligible for Part D. [3]

The dollar limits increase yearly.[ citation needed ]

2020 Medicare Part D Standard Drug Benefit

The following table shows the Medicare benefit breakdown (including the doughnut hole) for 2020.

2020 Medicare Part D Standard Benefit [4] [5]
Coverage PhaseTotal Annual Drug Cost [lower-alpha 1] Percentage Paid by BeneficiaryPercentage Paid by Plan
Deductible$0–$435 [lower-alpha 2] 100%0%
Initial Coverage$435–$4,02025% [lower-alpha 3] 75%
"Donut Hole"$4,020–$6,35025% [lower-alpha 4] 75%
Catastrophic Coverageover $6,350 [lower-alpha 5] 5% [lower-alpha 6] 95% [lower-alpha 7]
  1. ↑ Represents total negotiated drug price
  2. ↑ Usually no deductible for Tier 1 and Tier 2 drugs
  3. ↑ Or the Prescription Drug Plan (PDP) co-payment, if applicable
  4. ↑ Beneficiaries MUST pay 25%; Generic and brand cost apply differently to TrOOP in Donut Hole
  5. ↑ $6,350 Out-of-Pocket Threshold (TrOOP)
  6. ↑ Or $3.60 (generics) and $8.95 (brand-name), whichever is greater
  7. ↑ Plan pays 15%, Medicare pays 80%

The costs shown in the table above represent 2020 defined standard Medicare Part D prescription drug plan parameters released by the Centers for Medicare and Medicaid Services (CMS) in April 2017. [4] Individual Medicare Part D plans may choose to offer more generous benefits but must meet the minimum standards established by the defined standard benefit. [5]

The 2020 Medicare Part D standard benefit includes a deductible of $435 (amount beneficiaries pay out of pocket before insurance benefits kick in) and 25% coinsurance, up to $6,350. The catastrophic stage is reached after $6,350 of out-of-pocket spending, then beneficiaries pay 5% of the total drug cost or $3.60 (for generics) and $8.95 (for brand-name drugs), whichever is greater. [5]

2020 Donut Hole Discount: Part D enrollees will receive a 75% Donut Hole discount on the total cost of their brand-name drugs purchased while in the Donut Hole. The discount includes a 70% discount paid by the brand-name drug manufacturer and a 5% discount paid by your Medicare Part D plan. The 70% paid by the drug manufacturer combined with the 25% you pay, count toward your TrOOP or Donut Hole exit point. For example: If you reach the Donut Hole and purchase a brand-name medication with a retail cost of $100, you will pay $25 for the medication, and receive $95 credit toward meeting your 2020 total out-of-pocket spending limit.

Medicare Part D beneficiaries who reach the Donut Hole will also pay a maximum of 25% co-pay on generic drugs purchased while in the Coverage Gap (receiving a 75% discount). For example: If you reach the 2020 Donut Hole, and your generic medication has a retail cost of $100, you will pay $25. The $25 that you spend will count toward your TrOOP or Donut Hole exit point.

Low Income Subsidy

The Low-Income Subsidy (LIS), also known as "Extra Help" provides additional cost-sharing and premium assistance for eligible low-income Medicare Part D beneficiaries with incomes below 150% of the Federal Poverty Level and limited assets. Individuals who qualify for the Low-Income Subsidy (LIS) or who are also enrolled in Medicaid do not have a coverage gap. [6]

To qualify for the LIS, Medicare beneficiaries must qualify for full Medicaid benefits, be enrolled in Medicare Savings Programs (MSP), and receive Supplemental Security Income (SSI). These individuals automatically qualify for the subsidy and do not have to apply separately. Others may qualify after applying through their state Medicaid programs or through the Social Security Administration (SSA) and fulfil income and asset requirements. In a marketplace review conducted by the Kaiser Family Foundation in 2010, only 40% of eligible low-income beneficiaries who did not automatically qualify for the LIS actually received it. [7]

The majority of Medicare beneficiaries who qualify for the LIS will pay no premiums or deductibles and no more than $8.25 for each drug that their plan covers. In addition, beneficiaries with Extra Help are not penalized for late enrollment in a Part D plan. LIS recipients also benefit from a Continuous Special Enrollment Period to join or switch plans during any time of the year. They do not need to wait for the formal Annual Enrollment Period. Any changes made to their plans will be applied the following month. [8]

Low-Income Subsidy "Extra Help" Qualifications for 2017-2018 [9] [10]
Household SizeMaximum Annual Income [lower-alpha 1] Maximum Resources [lower-alpha 2]
Individual$18,090$13,820
Married Couple$24,360$27,600
  1. ↑ Does NOT include food stamp assistance, housing assistance, medical treatment and drugs
  2. ↑ Does NOT include home, car or life insurance policies

Impact on Medicare beneficiaries

The U.S. Department of Health and Human Services estimates that more than a quarter of Part D participants stop following their prescribed regimen of drugs when they hit the doughnut hole. [11]

Every Part D plan sponsor must offer at least one basic Part D plan. They may also offer enhanced plans that provide additional benefits. For 2008, the percentage of stand-alone Part D (PDP) plans to offer some form of coverage within the doughnut hole rose to 29 percent, up from 15 percent in 2006. The percentage of Medicare Advantage/Part D plans (MA-PD) plans offering some form of coverage in the coverage gap is 51 percent, up from 28 percent in 2006. The most common forms of gap coverage cover generic drugs only. [12]

Among Medicare Part D enrollees in 2007 who were not eligible for the low-income subsidies, 26 percent had spending high enough to reach the coverage gap. Fifteen percent of those reaching the coverage gap (four percent overall) had spending high enough to reach the catastrophic coverage level. Enrollees reaching the coverage gap stayed in the gap for just over four months on average. [13]

According to a study done in 2007, premiums for plans offering gap coverage are roughly double those of defined standard plans. The average monthly premium for stand-alone Part D plans (PDPs) with basic benefits that do not offer gap coverage is $30.14. The average monthly premium for plans that do offer some gap coverage is $63.29. In 2007, eight percent of beneficiaries enrolled in a PDP chose one with some gap coverage. Among beneficiaries in MA-PD plans, enrollment in plans offering gap coverage was 33 percent (up from 27 percent in 2006). [12]

Phase-out

Out-of-pocket cost component during gap phase-out (2015–2020) [2] : 6 
YearBrand-name drugsGeneric drugs
201545%65%
201645%58%
201740%51%
201835%44%
201930%37%
202025%25%

The Affordable Care Act (ACA), which was passed in 2010, ensured that the coverage gap or, so-called "doughnut hole", would be closing for patients on Medicare Part D. From 2017 to 2020, brand-name drug manufacturers and the federal government will be responsible for providing subsidies to patients in the doughnut hole. [14]

In an effort to close the coverage gap, in 2010, the Affordable Care Act provided a $250 rebate check for individuals whose drug expenses took them into the doughnut hole. The United States Department of Health and Human Services began mailing rebate checks in 2010. [11] Starting in 2011 until 2020, the coinsurance paid for prescriptions while in the coverage gap will decrease at a rate of 7% annually until beneficiaries will pay no more than 25% of the drug cost for their generic and brand name prescription purchases. [15] For instance, a 50% mark down off brand-name medications financed by the manufacturer and a 7% markdown off generic drugs by the government was introduced in 2011 for patients in the doughnut hole. These reductions on generic drug costs will continue to incrementally rise at a rate of 7% until 2019. The following year in 2020, an extra cost reduction will be imposed at 12%, equating to a total of 75% of the generic drug cost covered. [14] Similarly, for brand name drugs, the government will provide a subsidy at a rate of 2.5% beginning in 2013 and escalating to 25% in 2020. Thus, by 2020, Medicare Part D patients will only be responsible for paying 25% of the cost of covered generic and brand name prescription medications following payment of their deductible that year. Moreover, once patients enter the catastrophic threshold, they are only responsible for 5% of the drug cost. [14]

As of January 1, 2020, the coverage gap has closed. [16]

Related Research Articles

<span class="mw-page-title-main">Medicaid</span> United States social health care program for families and individuals with limited resources

In the United States, Medicaid is a government program that provides health insurance for adults and children with limited income and resources. The program is partially funded and primarily managed by state governments, which also have wide latitude in determining eligibility and benefits, but the federal government sets baseline standards for state Medicaid programs and provides a significant portion of their funding.

<span class="mw-page-title-main">Medicare (United States)</span> U.S. government health insurance for the old and disabled

Medicare is a government national health insurance program in the United States, begun in 1965 under the Social Security Administration (SSA) and now administered by the Centers for Medicare and Medicaid Services (CMS). It primarily provides health insurance for Americans aged 65 and older, but also for some younger people with disability status as determined by the SSA, including people with end stage renal disease and amyotrophic lateral sclerosis.

Prescription drug list prices in the United States continually are among the highest in the world. The high cost of prescription drugs became a major topic of discussion in the 21st century, leading up to the American health care reform debate of 2009, and received renewed attention in 2015. One major reason for high prescription drug prices in the United States relative to other countries is the inability of government-granted monopolies in the American health care sector to use their bargaining power to negotiate lower prices, and the American payer ends up subsidizing the world's R&D spending on drugs.

<span class="mw-page-title-main">Medicare Prescription Drug, Improvement, and Modernization Act</span>

The Medicare Prescription Drug, Improvement, and Modernization Act, also called the Medicare Modernization Act or MMA, is a federal law of the United States, enacted in 2003. It produced the largest overhaul of Medicare in the public health program's 38-year history.

Dual-eligible beneficiaries refers to those qualifying for both Medicare and Medicaid benefits. In the United States, approximately 9.2 million people are eligible for "dual" status. Dual-eligibles make up 14% of Medicaid enrollment, yet they are responsible for approximately 36% of Medicaid expenditures. Similarly, duals total 20% of Medicare enrollment, and spend 31% of Medicare dollars. Dual-eligibles are often in poorer health and require more care compared with other Medicare and Medicaid beneficiaries.

<span class="mw-page-title-main">Medicare Part D</span> United States prescription drug benefit for the elderly and disabled

Medicare Part D, also called the Medicare prescription drug benefit, is an optional United States federal-government program to help Medicare beneficiaries pay for self-administered prescription drugs. Part D was enacted as part of the Medicare Modernization Act of 2003 and went into effect on January 1, 2006. Under the program, drug benefits are provided by private insurance plans that receive premiums from both enrollees and the government. Part D plans typically pay most of the cost for prescriptions filled by their enrollees. However, plans are later reimbursed for much of this cost through rebates paid by manufacturers and pharmacies.

Health care prices in the United States of America describe market and non-market factors that determine pricing, along with possible causes as to why prices are higher than in other countries.

An out-of-pocket expense is the direct payment of money that may or may not be later reimbursed from a third-party source.

In the United States, a pharmacy benefit manager (PBM) is a third-party administrator of prescription drug programs for commercial health plans, self-insured employer plans, Medicare Part D plans, the Federal Employees Health Benefits Program, and state government employee plans. According to the American Pharmacists Association, "PBMs are primarily responsible for developing and maintaining the formulary, contracting with pharmacies, negotiating discounts and rebates with drug manufacturers, and processing and paying prescription drug claims." PBMs operate inside of integrated healthcare systems, as part of retail pharmacies, and as part of insurance companies.

The Retiree Drug Subsidy Program is a program offered by the Centers for Medicare & Medicaid Services (CMS) to reimburse health plan sponsors for a portion of their eligible expenses for retiree prescription drug benefits. This enables Plan Sponsors to continue providing drug coverage to their Medicare-eligible retirees at a lower cost.

In the United States, health insurance helps pay for medical expenses through privately purchased insurance, social insurance, or a social welfare program funded by the government. Synonyms for this usage include "health coverage", "health care coverage", and "health benefits". In a more technical sense, the term "health insurance" is used to describe any form of insurance providing protection against the costs of medical services. This usage includes both private insurance programs and social insurance programs such as Medicare, which pools resources and spreads the financial risk associated with major medical expenses across the entire population to protect everyone, as well as social welfare programs like Medicaid and the Children's Health Insurance Program, which both provide assistance to people who cannot afford health coverage.

Medicare Advantage is a capitated program for providing Medicare benefits in the United States. Under Part C, Medicare pays a sponsor a fixed payment. The sponsor then pays for the health care expenses of enrollees. Sponsors are allowed to vary the benefits from those provided by Medicare's Parts A and B as long as they provide the actuarial equivalent of those programs. The sponsors vary from primarily integrated health delivery systems to unions to other types of non profit charities to insurance companies. The largest sponsor is a hybrid: the non profit charity AARP using UnitedHealth.

Medication costs, also known as drug costs are a common health care cost for many people and health care systems. Prescription costs are the costs to the end consumer. Medication costs are influenced by multiple factors such as patents, stakeholder influence, and marketing expenses. A number of countries including Canada, parts of Europe, and Brazil use external reference pricing as a means to compare drug prices and to determine a base price for a particular medication. Other countries use pharmacoeconomics, which looks at the cost/benefit of a product in terms of quality of life, alternative treatments, and cost reduction or avoidance in other parts of the health care system. Structures like the UK's National Institute for Health and Clinical Excellence and to a lesser extent Canada's Common Drug Review evaluate products in this way.

<span class="mw-page-title-main">Health Care and Education Reconciliation Act of 2010</span> United States law

The Health Care and Education Reconciliation Act of 2010 is a law that was enacted by the 111th United States Congress, by means of the reconciliation process, in order to amend the Affordable Care Act (ACA). The law includes the Student Aid and Fiscal Responsibility Act, which was attached as a rider.

Health care finance in the United States discusses how Americans obtain and pay for their healthcare, and why U.S. healthcare costs are the highest in the world based on various measures.

The 340B Drug Pricing Program is a US federal government program created in 1992 that requires drug manufacturers to provide outpatient drugs to eligible health care organizations and covered entities at significantly reduced prices. The intent of the program is to allow covered entities to "stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services." Maintaining services and lowering medication costs for patients is consistent with the purpose of the program, which is named for the section authorizing it in the Public Health Service Act (PHSA) It was enacted by Congress as part of a larger bill signed into law by President George H. W. Bush.

The Affordable Care Act (ACA) is divided into 10 titles and contains provisions that became effective immediately, 90 days after enactment, and six months after enactment, as well as provisions phased in through to 2020. Below are some of the key provisions of the ACA. For simplicity, the amendments in the Health Care and Education Reconciliation Act of 2010 are integrated into this timeline.

Specialty drugs or specialty pharmaceuticals are a recent designation of pharmaceuticals classified as high-cost, high complexity and/or high touch. Specialty drugs are often biologics—"drugs derived from living cells" that are injectable or infused. They are used to treat complex or rare chronic conditions such as cancer, rheumatoid arthritis, hemophilia, H.I.V. psoriasis, inflammatory bowel disease and hepatitis C. In 1990 there were 10 specialty drugs on the market, around five years later nearly 30, by 2008 200, and by 2015 300.

Yuting Zhang is a professor of health economics at the University of Melbourne, and an expert on economic evaluations of health policy and healthcare reforms. She is a journal editor, award recipient, and has written numerous articles in influential journals in her field.

<span class="mw-page-title-main">Elijah Cummings Lower Drug Costs Now Act</span> Proposed legislation

The Elijah Cummings Lower Drug Costs Now Act is proposed legislation in the 117th United States Congress. The bill is designed to lower prescription drug costs in the United States. Notably, the law gives the federal government the power to negotiate prescription drug prices. The legislation takes the name of late Maryland Representative Elijah Cummings.

References

  1. ↑ "What is TrOOP or True Out-Of-Pocket Costs". Q1Medicare.com. Q1Group LLC. Archived from the original on October 31, 2020. Retrieved February 1, 2021.
  2. 1 2 Centers for Medicare and Medicaid Services (January 2015). "Closing the Coverage Gap—Medicare Prescription Drugs Are Becoming More Affordable" (PDF). Medicare.gov. U.S. Department of Health and Human Services. Archived from the original (PDF) on February 21, 2015.
  3. ↑ Liu FX, Alexander GC, Crawford SY, Pickard AS, Hedeker D, Walton SM (August 2011). "Impact of Medicare Part D on Emergency Department Use, Hospitalizations, and Preference-based Health Utility". Health Services Research. 46 (4): 1104–1123. doi:10.1111/j.1475-6773.2011.01273.x. PMC   3165180 . PMID   21609328.
  4. 1 2 LLC, Q1GROUP. "2019 Medicare Part D Outlook". q1medicare.com. Retrieved March 18, 2019.{{cite web}}: CS1 maint: numeric names: authors list (link)
  5. 1 2 3 "The Medicare Part D Prescription Drug Benefit". The Henry J. Kaiser Family Foundation. October 2, 2017. Retrieved November 6, 2017.
  6. ↑ LLC, Q1GROUP. "Medicaid, Extra Help and LIS". q1medicare.com. Retrieved November 6, 2017.{{cite web}}: CS1 maint: numeric names: authors list (link)
  7. ↑ Summer, Laura. "THE MEDICARE PART D LOW-INCOME SUBSIDY PROGRAM: Experience to Date and Policy Issues for Consideration" (PDF). Kaiser Family Foundation. Retrieved November 6, 2017.
  8. ↑ "Low Income Subsidy (LIS) - Medicare Extra Help | NCOA". NCOA. May 7, 2015. Retrieved November 7, 2017.
  9. ↑ "Extra Help with Medicare Prescription Drug Plan Costs". www.ssa.gov. Retrieved November 6, 2017.
  10. ↑ LLC, Q1GROUP. "What is NOT counted toward Income by Social Security when applying for extra help with Medicare prescription drug plan costs?". q1medicare.com. Retrieved November 6, 2017.{{cite web}}: CS1 maint: numeric names: authors list (link)
  11. 1 2 Claffey, Jason (August 14, 2010). "Medicare 'Doughnut Hole' Checks in the Mail". Foster's Daily Democrat . Gatehouse Media. Retrieved December 26, 2012.
  12. 1 2 Hoadley, Jack; Thompson, Jennifer; Hargrave, Elizabeth; Merrell, Katie; Cubanski, Juliette; Neuman, Tricia (October 30, 2007). Medicare Part D 2008 Data Spotlight: The Coverage Gap (Report). Kaiser Family Foundation.
  13. ↑ Hoadley, Jack; Hargrave, Elizabeth; Cubanski, Juliette; Neuman, Tricia (August 21, 2008). The Medicare Part D Coverage Gap: Costs and Consequences in 2007 (PDF) (Report). Kaiser Family Foundation. Archived from the original (PDF) on December 15, 2012. Retrieved December 26, 2012.
  14. 1 2 3 Shrank, William H.; Choudhry, Niteesh K. (February 17, 2011). "Time to Fill the Doughnuts — Health Care Reform and Medicare Part D". New England Journal of Medicine. 364 (7): 598–601. doi:10.1056/NEJMp1011625. ISSN   0028-4793. PMID   21247308.
  15. ↑ LLC, Q1GROUP. "The Medicare Part D Donut Hole Discount (2011 to 2020)". q1medicare.com. Retrieved November 6, 2017.{{cite web}}: CS1 maint: numeric names: authors list (link)
  16. ↑ Span, Paula (January 17, 2020). "Medicare's Part D Doughnut Hole Has Closed! Mostly. Sorta". The New York Times. ISSN   0362-4331 . Retrieved August 24, 2021.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.